作者: Trine Lembrecht Jørgensen , Jesper Hallas , Lotte Holm Land , Jørn Herrstedt
DOI: 10.1016/J.JGO.2010.06.003
关键词:
摘要: Abstract Older adults have an increased burden of comorbidity which increases their risk being exposed to polypharmacy. Because underrepresentation elderly cancer patients in clinical trials, knowledge the influence and polypharmacy on these patients' response tolerance antineoplastic treatment is sparse. We reviewed literature impact factors outcome. Large population-based studies all found association between survival among patients. However, we need focus cancer-specific conclude disease its treatment. Prospective are needed